|
|||||
|
|
Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1 |
||
| Authors: | Safaa M. Kishk Kirsty J. McLean Sakshi Sood Mohamed A. Helal Mohamed S. Gomaa Ismail Salama Samia M. Mostafa Luiz Pedro S. de Carvalho Andrew W. Munro Claire Simons | |
| Affiliation: | 1. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK;2. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt;3. Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK;4. Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK;5. Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza 12588, Egypt;6. Department of Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia | |
| Abstract: | The rise in multidrug resistant (MDR) cases of tuberculosis (TB) has led to the need for the development of TB drugs with different mechanisms of action. The genome sequence of Mycobacterium tuberculosis (Mtb) revealed twenty different genes coding for cytochrome P450s. CYP121A1 catalyzes a C | |
| Keywords: | CYP121A1 1,4-Dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives Binding affinity assays Molecular modelling | |
| 本文献已被 ScienceDirect 等数据库收录！ | ||